 |
인쇄하기
취소
|
Shinil to agree joint R&D agreement for anti-cancer drug.
Shinil pharmaceutical company announced on March 13 that the company agreed with Biorernex Inc. for the joint R&D of 'Amina-X" project, a new anti-cancer therapy after changing the name of project "BVX".
The project name change was due to the withdrawal of the exclusive use licence of the fundamental technology for BVX anti-cancer drug originally provided to Wonbio Inc.
The agreement re...
The project name change was due to the withdrawal of the exclusive use licence of the fundamental technology for BVX anti-cancer drug originally provided to Wonbio Inc.
The agreement re...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.